NCT07048496 Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
| NCT ID | NCT07048496 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Bladder Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-07-05 |
| Primary Completion | 2027-02-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-07-05 with a primary completion date of 2027-02-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in the second cohort will be enrolled in a conversational agent to measure patient symptoms and quality of life and improve self-efficacy.
Eligibility Criteria
Inclusion Criteria: Inclusion criteria for patients in Cohort 1 * Age 18 years or older; * completed intravesical treatment for non-muscle invasive bladder cancer within the past year Cohort 1 inclusion criteria for key stakeholders * Age 18 years or older; * experience with the delivery of BCG delivery for more than 2 years Cohort 2 inclusion criteria * Age 18 years or older; * diagnosed with non-muscle invasive bladder cancer and prescribed BCG for initial therapy Exclusion Criteria: Cohort 1 exclusion criteria • inability to provide informed consent Cohort 2 exclusion criteria * inability to provide informed consent * inability to undergo catheterization (i.e. - history of urethral stricture) * inability to receive BCG therapy (i.e. - previous reaction with BCG) * no access to mobile phone * inability to respond to written conversations in English
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07048496 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bladder Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07048496 currently recruiting?
Yes, NCT07048496 is actively recruiting participants. Contact the research team at daniel.lee4@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07048496 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07048496 clinical trial?
NCT07048496 is sponsored by Abramson Cancer Center at Penn Medicine. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.